Advocate
The LRF Advocacy Program provides volunteers with the tools necessary to garner support for public policies important to the lymphoma community
The LRF Advocacy Program provides volunteers with the tools necessary to garner support for public policies important to the lymphoma community
The CAR T-cell therapy NXC-201 has received orphan drug designation by the European Commission for patients with multiple myeloma.
Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer.
Both inflammatory activation and dysregulation of the immune response in the bone marrow niche are key players in the pathogenesis of myelodysplastic syndromes (MDS). Manja…
Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.
Rebecca Klisovic, MD, discusses 4 case studies of patients who presented with varying types of myelofibrosis and the appropriate treatment avenues for each patient.
Analysis of long-term findings from the phase III Dana-Farber Cancer Institute Trial 05-043 showed that whole-pelvic radiation therapy was associated with favorable survival outcomes vs…
A phase 2 trial of stenoparib in advanced recurrent ovarian cancer has been closed early to enable a follow-on trial with FDA regulatory intent.
Patients with CLL/SLL who received second-line venetoclax experienced monthly cost savings compared with those who received a second-line BTK inhibitor.
Amandeep Salhotra, MD, discusses the feasibility and safety of Orca-T graft in patients undergoing allogeneic transplant for hematologic malignancies.
An abstract is unavailable.